Exploring hub genes and their expression status in the inflamed synovium is a critical step in defining new targets for the diagnosis or treatment of RA, especially for the ACPA-negative RA patients whose condition could not be well managed at the developing stage due to negative index of clinical symptoms and serologic testing. Here, PRTN3 is linked to rheumatoid arthritis.